Pre-exposure prophylaxis HIV drugs market is anticipated to grow at a significant CAGR during the forecast period. Pre-exposure prophylaxis drugs are the medicines that are to be taken so as to prevent infection with HIV. Pre-exposure prophylaxis is highly effective for preventing HIV when taken as prescribed. The major driving factors contributing to the market growth include the rising prevalence and burden of HIV, growing investment in R&D related to these drugs coupled with the rise in the availability of novel drugs that pose better efficacy than ever before. For instance, as per the US Department of Health & Human Services, in 2018, there were nearly 37.9 million people globally living with HIV/AIDS. An estimated 1.7 million individuals globally became newly infected with HIV in 2018.
These drugs are majorly available in a number of categories that broadly include Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and others. Currently, pre-exposure prophylaxis drugs are considered to be the basis of HIV/AIDS treatment, since there is no solid cure or a preventive vaccine available for HIV. Thus, the presence of a huge patient pool leads to increasing demand for pre-exposure prophylaxis drugs for the treatment of HIV, which is projected to drive the growth of the market during the forecast period.
Some key players operating in the market include Gilead Sciences, Inc., Mylan N.V., and Cipla Ltd., among others. These market players are focusing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launches and development in the existing product portfolio, and so on. In May 2019, Gilead Sciences, Inc. declared that it will donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the US Centers for Disease Control and Prevention (CDC) in support of national efforts to help prevent HIV and end the epidemic. This is part of Gilead’s wide ongoing initiatives to support ensure that everyone who can benefit from PrEP can access it. Gilead will provide to CDC up to 2.4 million bottles of Truvada annually for uninsured Americans at risk for HIV.
To Request a Sample of our Report on Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market: https://www.omrglobal.com/request-sample/pre-exposure-prophylaxis-hiv-drugs-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2021
- Forecast period- 2023-2030
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape: Gilead Sciences, Inc., Mylan N.V., and Cipla Ltd., among others.
Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market Report by Segment
By Drugs
- Truvada
- Descovy
By Dosage Form
- Oral
- Topical
A full Report of Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market is Available at: https://www.omrglobal.com/industry-reports/pre-exposure-prophylaxis-hiv-drugs-market
Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404